Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection.

Autor: Ferry T; Service de Maladies Infectieuses et Tropicales, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France. tristan.ferry@univ-lyon1.fr.; Université Claude Bernard Lyon 1, Villeurbanne, France. tristan.ferry@univ-lyon1.fr.; Centre de Référence des Infections Ostéo-Articulaires Complexes de Lyon (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France. tristan.ferry@univ-lyon1.fr.; Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France. tristan.ferry@univ-lyon1.fr., Kolenda C; Université Claude Bernard Lyon 1, Villeurbanne, France.; Centre de Référence des Infections Ostéo-Articulaires Complexes de Lyon (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.; Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.; Institut des Agents Infectieux, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France., Laurent F; Université Claude Bernard Lyon 1, Villeurbanne, France.; Centre de Référence des Infections Ostéo-Articulaires Complexes de Lyon (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.; Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.; Institut des Agents Infectieux, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France., Leboucher G; Pharmacie Hospitalière, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France., Merabischvilli M; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120, Brussels, Belgium., Djebara S; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120, Brussels, Belgium., Gustave CA; Université Claude Bernard Lyon 1, Villeurbanne, France.; Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.; Institut des Agents Infectieux, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France., Perpoint T; Service de Maladies Infectieuses et Tropicales, Hôpital de la Croix-rousse, Hospices Civils de Lyon, Lyon, France., Barrey C; Service de Neurochirurgie, Chirurgie du Rachis et de la Moëlle Épinière, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France., Pirnay JP; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120, Brussels, Belgium., Resch G; Centre of Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital, Lausanne, Switzerland.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Jul 22; Vol. 13 (1), pp. 4239. Date of Electronic Publication: 2022 Jul 22.
DOI: 10.1038/s41467-022-31837-9
Abstrakt: Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance. Lytic bacteriophages (phages for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms. Here we report on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, we set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time. After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: